Literature DB >> 26297735

Glioblastomas require integrin αvβ3/PAK4 signaling to escape senescence.

Aleksandra Franovic1, Kathryn C Elliott1, Laetitia Seguin1, M Fernanda Camargo1, Sara M Weis1, David A Cheresh2.   

Abstract

Integrin αvβ3 has been implicated as a driver of aggressive and metastatic disease, and is upregulated during glioblastoma progression. Here, we demonstrate that integrin αvβ3 allows glioblastoma cells to counteract senescence through a novel tissue-specific effector mechanism involving recruitment and activation of the cytoskeletal regulatory kinase PAK4. Mechanistically, targeting either αvβ3 or PAK4 led to emergence of a p21-dependent, p53-independent cell senescence phenotype. Notably, glioblastoma cells did not exhibit a similar requirement for either other integrins or additional PAK family members. Moreover, αvβ3/PAK4 dependence was not found to be critical in epithelial cancers. Taken together, our findings established that glioblastomas are selectively addicted to this pathway as a strategy to evade oncogene-induced senescence, with implications that inhibiting the αvβ3-PAK4 signaling axis may offer novel therapeutic opportunities to target this aggressive cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26297735      PMCID: PMC4631634          DOI: 10.1158/0008-5472.CAN-15-0988

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors.

Authors:  C L Gladson
Journal:  J Neuropathol Exp Neurol       Date:  1996-11       Impact factor: 3.685

Review 2.  The signals and pathways activating cellular senescence.

Authors:  Ittai Ben-Porath; Robert A Weinberg
Journal:  Int J Biochem Cell Biol       Date:  2004-12-30       Impact factor: 5.085

3.  Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.

Authors:  T J MacDonald; T Taga; H Shimada; P Tabrizi; B V Zlokovic; D A Cheresh; W E Laug
Journal:  Neurosurgery       Date:  2001-01       Impact factor: 4.654

Review 4.  Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence.

Authors:  Lars-Gunnar Larsson
Journal:  Semin Cancer Biol       Date:  2011-10-24       Impact factor: 15.707

Review 5.  Inside and out: the activities of senescence in cancer.

Authors:  Pedro A Pérez-Mancera; Andrew R J Young; Masashi Narita
Journal:  Nat Rev Cancer       Date:  2014-07-17       Impact factor: 60.716

6.  An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Authors:  Laetitia Seguin; Shumei Kato; Aleksandra Franovic; M Fernanda Camargo; Jacqueline Lesperance; Kathryn C Elliott; Mayra Yebra; Ainhoa Mielgo; Andrew M Lowy; Hatim Husain; Tina Cascone; Lixia Diao; Jing Wang; Ignacio I Wistuba; John V Heymach; Scott M Lippman; Jay S Desgrosellier; Sudarshan Anand; Sara M Weis; David A Cheresh
Journal:  Nat Cell Biol       Date:  2014-04-20       Impact factor: 28.824

7.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Roger Stupp; Monika E Hegi; Thierry Gorlia; Sara C Erridge; James Perry; Yong-Kil Hong; Kenneth D Aldape; Benoit Lhermitte; Torsten Pietsch; Danica Grujicic; Joachim Peter Steinbach; Wolfgang Wick; Rafał Tarnawski; Do-Hyun Nam; Peter Hau; Astrid Weyerbrock; Martin J B Taphoorn; Chiung-Chyi Shen; Nalini Rao; László Thurzo; Ulrich Herrlinger; Tejpal Gupta; Rolf-Dieter Kortmann; Krystyna Adamska; Catherine McBain; Alba A Brandes; Joerg Christian Tonn; Oliver Schnell; Thomas Wiegel; Chae-Yong Kim; Louis Burt Nabors; David A Reardon; Martin J van den Bent; Christine Hicking; Andriy Markivskyy; Martin Picard; Michael Weller
Journal:  Lancet Oncol       Date:  2014-08-19       Impact factor: 41.316

8.  Protein kinase D-mediated phosphorylation at Ser99 regulates localization of p21-activated kinase 4.

Authors:  Ligia I Bastea; Heike Döppler; Sarah E Pearce; Nisha Durand; Samantha J Spratley; Peter Storz
Journal:  Biochem J       Date:  2013-10-15       Impact factor: 3.857

Review 9.  Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.

Authors:  Dominik Sturm; Sebastian Bender; David T W Jones; Peter Lichter; Jacques Grill; Oren Becher; Cynthia Hawkins; Jacek Majewski; Chris Jones; Joseph F Costello; Antonio Iavarone; Kenneth Aldape; Cameron W Brennan; Nada Jabado; Stefan M Pfister
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

10.  Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma.

Authors:  D Kesanakurti; C Chetty; D Rajasekhar Maddirela; M Gujrati; J S Rao
Journal:  Cell Death Dis       Date:  2012-12-20       Impact factor: 8.469

View more
  14 in total

Review 1.  Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis.

Authors:  Alexandra Desnoyers; Carlos González; Pedro Pérez-Segura; Atanasio Pandiella; Eitan Amir; Alberto Ocaña
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

2.  Retinoic acid inducible gene-I slows down cellular senescence through negatively regulating the integrin β3/p38 MAPK pathway.

Authors:  Junmei Zhao; Xinyi Jiang; Li Yan; Jian Lin; Hezhou Guo; Shanhe Yu; Baixin Ye; Jiang Zhu; Wu Zhang
Journal:  Cell Cycle       Date:  2019-10-09       Impact factor: 4.534

3.  Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub-5 Ultrafine Iron Oxide Nanoparticles.

Authors:  Yuancheng Li; Manman Xie; Joshua B Jones; Zhaobin Zhang; Zi Wang; Tu Dang; Xinyu Wang; Malgorzata Lipowska; Hui Mao
Journal:  Adv Healthc Mater       Date:  2022-05-06       Impact factor: 11.092

4.  Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Authors:  Érika Cosset; Sten Ilmjärv; Valérie Dutoit; Kathryn Elliott; Tami von Schalscha; Maria F Camargo; Alexander Reiss; Toshiro Moroishi; Laetitia Seguin; German Gomez; Jung-Soon Moo; Olivier Preynat-Seauve; Karl-Heinz Krause; Hervé Chneiweiss; Jann N Sarkaria; Kun-Liang Guan; Pierre-Yves Dietrich; Sara M Weis; Paul S Mischel; David A Cheresh
Journal:  Cancer Cell       Date:  2017-11-30       Impact factor: 31.743

5.  Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4.

Authors:  Zhiheng Li; Xiaolu Li; Lixiao Xu; Yanfang Tao; Chun Yang; Xiaolan Chen; Fang Fang; Yi Wu; Xin Ding; He Zhao; Mei Li; Guanghui Qian; Yunyun Xu; Junli Ren; Weiwei Du; Jian Wang; Jun Lu; Shaoyan Hu; Jian Pan
Journal:  Oncol Rep       Date:  2017-09-22       Impact factor: 3.906

Review 6.  RGD-Binding Integrins in Head and Neck Cancers.

Authors:  Hanadi Talal Ahmedah; Laurence H Patterson; Steven D Shnyder; Helen M Sheldrake
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

7.  Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway.

Authors:  Valentina Rapisarda; Michela Borghesan; Veronica Miguela; Vesela Encheva; Ambrosius P Snijders; Amaia Lujambio; Ana O'Loghlen
Journal:  Cell Rep       Date:  2017-03-07       Impact factor: 9.423

8.  MiR-124 inhibits the migration and invasion of human hepatocellular carcinoma cells by suppressing integrin αV expression.

Authors:  Qian Qian Cai; Yi Wei Dong; Rong Wang; Bing Qi; Jun Xia Guo; Jing Pan; Yuan Yuan Liu; Chun Yi Zhang; Xing Zhong Wu
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

Review 9.  Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Authors:  Laure Malric; Sylvie Monferran; Julia Gilhodes; Sabrina Boyrie; Perrine Dahan; Nicolas Skuli; Julie Sesen; Thomas Filleron; Aline Kowalski-Chauvel; Elizabeth Cohen-Jonathan Moyal; Christine Toulas; Anthony Lemarié
Journal:  Oncotarget       Date:  2017-08-21

10.  Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells.

Authors:  E L Kavanagh; S Lindsay; M Halasz; L C Gubbins; K Weiner-Gorzel; M H Z Guang; A McGoldrick; E Collins; M Henry; A Blanco-Fernández; P O Gorman; P Fitzpatrick; M J Higgins; P Dowling; A McCann
Journal:  Oncogenesis       Date:  2017-10-09       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.